Back

Adverse childhood trauma and reoccurrence of illness impact the gut microbiome, which affects suicidal behaviors and the phenome of major depression: towards enterotypic-phenotypes

Maes, M.; Vasupanrajit, A.; Jirakran, K.; Klomkliew, P.; Chanchaem, P.; Tunvirachaisakul:, C.; Plaimas, K.; Suratanee, A.; Payungporn, S.

2023-01-18 psychiatry and clinical psychology
10.1101/2023.01.14.23284564 medRxiv
Show abstract

The first publication demonstrating that major depressive disorder (MDD) is associated with alterations in the gut microbiota appeared in 2008 (Maes et al., 2008). The purpose of the present study is to delineate a) the microbiome signature of the phenome of depression, including suicidal behaviours and cognitive deficits; the effects of adverse childhood experiences (ACE) and recurrence of illness index (ROI) on the microbiome; and the microbiome signature of lowered high-density lipoprotein cholesterol (HDLc). We determined isometric log-ratio abundances or prevalence of gut microbiome phyla, genera, and species by analyzing stool samples from 37 healthy Thai controls and 32 MDD patients using 16S rDNA sequencing. Six microbiome taxa accounted for 36% of the variance in the depression phenome, namely Hungatella and Fusicatenibacter (positive associations) and Butyricicoccus, Clostridium, Parabacteroides merdae, and Desulfovibrio piger (inverse association). This profile (labeled enterotype 1) indicates compositional dysbiosis, is strongly predicted by ACE and ROI, and is linked to suicidal behaviours. A second enterotype was developed that predicted a decrease in HDLc and an increase in the atherogenic index of plasma (Bifidobacterium, P. merdae, and Romboutsia were positively associated, while Proteobacteria and Clostridium sensu stricto were negatively associated). Together, enterotypes 1 and 2 explained 40.4% of the variance in the depression phenome, and enterotype 1 in conjunction with HDLc explained 39.9% of the variance in current suicidal behaviours. In conclusion, the microimmuneoxysome is a potential new drug target for the treatment of severe depression and suicidal behaviours, and possibly for the prevention of future episodes.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Translational Psychiatry
219 papers in training set
Top 0.1%
18.7%
2
Journal of Affective Disorders
81 papers in training set
Top 0.2%
12.5%
3
Acta Neuropsychiatrica
12 papers in training set
Top 0.1%
12.5%
4
Brain, Behavior, & Immunity - Health
27 papers in training set
Top 0.1%
6.3%
50% of probability mass above
5
Brain, Behavior, and Immunity
105 papers in training set
Top 0.3%
6.3%
6
European Neuropsychopharmacology
15 papers in training set
Top 0.1%
4.9%
7
Molecular Psychiatry
242 papers in training set
Top 0.7%
4.0%
8
Journal of Psychiatric Research
28 papers in training set
Top 0.1%
4.0%
9
Cells
232 papers in training set
Top 1%
2.6%
10
Scientific Reports
3102 papers in training set
Top 53%
1.9%
11
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.9%
12
Journal of Advanced Research
15 papers in training set
Top 0.2%
1.8%
13
Psychoneuroendocrinology
33 papers in training set
Top 0.2%
1.5%
14
Psychological Medicine
74 papers in training set
Top 1%
1.0%
15
PLOS ONE
4510 papers in training set
Top 62%
1.0%
16
Psychiatry Research
35 papers in training set
Top 1%
0.9%
17
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
22 papers in training set
Top 0.3%
0.9%
18
International Journal of Molecular Sciences
453 papers in training set
Top 13%
0.9%
19
Journal of Personalized Medicine
28 papers in training set
Top 1%
0.8%
20
Brain Sciences
52 papers in training set
Top 2%
0.7%
21
Neuropharmacology
60 papers in training set
Top 0.7%
0.7%
22
NeuroImage: Clinical
132 papers in training set
Top 4%
0.7%
23
Alcohol
15 papers in training set
Top 0.3%
0.7%
24
Behavioural Processes
15 papers in training set
Top 0.4%
0.7%
25
BMC Medicine
163 papers in training set
Top 8%
0.6%